Literature DB >> 1168693

The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b).

J D Gitlin, F S Rosen, P J Lachmann.   

Abstract

The fixation of the third component of complement (C3) results in many important biological phenomenon, among which are (a) immune adherence (1), (b) enhancement of phagocytosis (2,3), (c) the release of an anaphylatoxin which is a potent releaser of histamine (4), and (d) the feedback activation of the alternative pathway (5,6). The physiological mechanisms involving C3 fixation require the generation of a C3 convertase which may occur by two separate pathways. C3 convertase can be generated, in the form of C42, by the so-called classical pathway of activation or in the form C3b,B by the alternative or properdin pathway (7). In both cases, C3 is converted to C3b by cleavage of a small peptide, C3a. Normal human serum contains an inactivator of activated C3b. This C2b inactivator or conglutinogen-activating factor (KAF) has been shown to inhibit both immune hemolysis and the immune adherence properties of C3b and to cause cleavage of C3b in the fixed and fluid- phase stages (8-11). Although it is known that the C3b inactivator is not depleted during its reaction with C3b and that C3b treated with the C3b inactivator becomes extremely sensitive to proteolytic digestion by trypsin and "trypsin-like" enzymes (9), the exact molecular nature of the action of the C3b inactivator on C3b has not been studied. In an effort to delineate the products of this interaction, purified C3b and C3b inactivator were allowed to react for various specific lengths of time and the products of these reactions were then analyzed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1168693      PMCID: PMC2189781          DOI: 10.1084/jem.141.5.1221

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.

Authors:  V Brade; G D Lee; A Nicholson; H S Shin; M M Mayer
Journal:  J Immunol       Date:  1973-11       Impact factor: 5.422

2.  Further studies on the C3b inactivator or conglutinogen activating factor (KAF).

Authors:  P J Lachmann; P Nicol; W P Aston
Journal:  Immunochemistry       Date:  1973-10

3.  Anaphylatoxin formation by purified human C'1 esterase.

Authors:  W Dias da Silva; I H Lepow
Journal:  J Immunol       Date:  1965-12       Impact factor: 5.422

4.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

5.  Deficiency of C3 inactivator in man.

Authors:  N Abramson; C A Alper; P J Lachmann; F S Rosen; J H Jandl
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

6.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

7.  Inactivator of the third component of complement as an inhibitor in the properdin pathway.

Authors:  C A Alper; F S Rosen; P J Lachmann
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

8.  The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors.

Authors:  R B Johnston; M R Klemperer; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

2.  Inhibition of neutrophil function by fluid phase C3b of complement.

Authors:  J D Ogle; C K Ogle; J W Alexander
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

3.  Differentiation of C3b receptors on human lymphocytes, phagocytes, erythrocytes and renal glomerulus cells by monoclonal antibodies.

Authors:  M P Dierich; H H Mussel; O Scheiner; T Ehlen; R Burger; H Peters; M Schmitt; S Trepke; G Zimmer
Journal:  Immunology       Date:  1982-01       Impact factor: 7.397

4.  C3b inactivator deficiency with immune complex manifestations.

Authors:  P Solal-Celigny; M Laviolette; J Hebert; P C Atkins; M Sirois; G Brun; G Lehner-Netsch; J M Delâge
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

5.  Cyclic nucleotides and their relationship to complement-component-C2 synthesis by human monocytes.

Authors:  D Lappin; D W Riches; B Damerau; K Whaley
Journal:  Biochem J       Date:  1984-09-01       Impact factor: 3.857

6.  Activated C3 (C3b) in the nephritic glomerulus.

Authors:  C Pan; C F Strife; A J McAdams; C D West
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

7.  Binding of immunoglobulin- and complement-coated erythrocytes to human neutrophil subpopulations.

Authors:  S C Whited; M Santaella; M M Frank; T Gaither; J I Gallin
Journal:  Inflammation       Date:  1981-06       Impact factor: 4.092

8.  Role of C3 in the control of monocyte C2 production.

Authors:  A O Hamilton; L Morrison; W S Kilpatrick; D Lappin; J C Bensa; D W Riches; K Whaley
Journal:  Immunology       Date:  1984-01       Impact factor: 7.397

9.  Isolation and biochemical characterization of the iC3b receptor of Candida albicans.

Authors:  S Alaei; C Larcher; C Ebenbichler; W M Prodinger; J Janatova; M P Dierich
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

10.  Steroids inhibit activation of the alternative-amplification pathway of complement.

Authors:  B D Packard; J M Weiler
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.